Enovis reaffirmed its 2026 guidance during its second-quarter earnings call, targeting free cash flow conversion of greater than 25%. CEO Damien McDonald reported organic growth of 5%, driven by 6% organic growth in Recon and 3% in P&R, with U.S. Recon led by 8% organic growth in Hips and Knees. CFO Phillip Berry noted second-quarter sales of $583 million, adjusted gross margin of 62%, adjusted EBITDA margin of 17.9%, and adjusted earnings per share of $0.90. The company expects a seasonally softer third quarter followed by sales acceleration in the fourth quarter, supported by the full commercial launch of the Arvis system in the U.S. and continued adoption of the Nebula platform.
Enovis CorpReaffirmed 2026 guidance and targets over 25% free cash flow conversion, with Q2 results meeting expectations.
